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Abstract. Peptide and protein drugs have become the new generation of therapeutics, yet most of them
are only available as injections, and reports on oral local intestinal delivery of peptides and proteins are
quite limited. The aim of this work was to develop and evaluate a water-in-oil (w/o) microemulsion
system in vitro and in vivo for local intestinal delivery of water-soluble peptides after oral administration.
A fluorescent labeled peptide, 5-(and-6)-carboxytetramethylrhodamine labeled HIV transactivator
protein TAT (TAMRA-TAT), was used as a model peptide. Water-in-oil microemulsions consisting of
Miglyol 812, Capmul MCM, Tween 80, and water were developed and characterized in terms of
appearance, viscosity, conductivity, morphology, and particle size analysis. TAMRA-TAT was loaded and
its enzymatic stability was assessed in modified simulated intestinal fluid (MSIF) in vitro. In in vivo
studies, TAMRA-TAT intestinal distribution was evaluated using fluorescence microscopy after
TAMRA-TAT microemulsion, TAMRA-TAT solution, and placebo microemulsion were orally gavaged
to mice. The half-life of TAMRA-TAT in microemulsion was enhanced nearly three-fold compared to
that in the water solution when challenged by MSIF. The treatment with TAMRA-TAT microemulsion
after oral administration resulted in greater fluorescence intensity in all intestine sections (duodenum,
jejunum, ileum, and colon) compared to TAMRA-TAT solution or placebo microemulsion. The in vitro
and in vivo studies together suggested TAMRA-TATwas better protected in the w/o microemulsion in an
enzyme-containing environment, suggesting that the w/o microemulsions developed in this study may
serve as a potential delivery vehicle for local intestinal delivery of peptides or proteins after oral
administration.
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INTRODUCTION
With biotechnological advances, peptide- and protein-
based drugs have gained an increasing and irreplaceable
share of the pharmaceutical market. However, the majority of
peptide and protein pharmaceuticals such as insulin, mono-
clonal antibody-based drugs, human growth hormone, and
interferon-α require administration as injections (1). As a
consequence, more widespread applications to treat chronic
conditions where the patient can self-medicate are limited.
The past decades have seen a great deal of efforts to develop
non-parenteral routes of delivery for peptides and proteins.
Oral delivery may be the most attractive route yet arguably
the most challenging due to poor chemical and physical
stability of these molecules. Being polymers of amino acids
linked together by peptide bonds with specific three-dimen-
sional conformations (2), most peptides and proteins are
hydrophilic with poor membrane permeability, susceptible to
proteolytic degradation, and low gastric pH. To overcome
these obstacles, many strategies have been applied, such as
macromolecular chemical modifications (3–5) and simple and
complex formulation approaches (6–8). Among various
formulation approaches, microemulsions (2,9) have received
considerable attention for the oral delivery of peptides and
proteins, especially for enhanced oral absorption (10,11).
Microemulsions are thermodynamically stable disper-
sions of two immiscible liquids stabilized by surfactants (11),
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andmainly classified into three categories: (a) oil-in-water (o/w),
(b) water-in-oil (w/o), and (c) bicontinuousmicroemulsions. Oil-
in-water microemulsions are promising in improving the bio-
availability of hydrophobic molecules, including hydrophobic
peptides, such as cyclosporine A (12). Water-in-oil micro-
emulsions, on the other hand, have shown potential to improve
the oral delivery of hydrophilic peptides or proteins
(10,11,13,14). The mechanisms proposed for improved bioavail-
ability using w/o microemulsions were based on increased
protection from luminal enzymatic degradation and/or enhanc-
er-induced structural and fluidity changes in the mucosal
membrane (13,15,16). The safety evaluation of several orally
delivered w/o microemulsions has been investigated (10,11,14),
and histological examination showed no intestinal tissue damage
or irritation upon acute dosing of the specific vehicles.
However, so far, most investigations of w/o microemul-
sions for peptide or protein oral delivery have been focused
on systemic absorption, while the local intestinal delivery of
peptides or proteins for the treatment of local pathologies has
been less studied. In this work, the potential of w/o micro-
emulsions for local intestinal delivery of water-soluble
peptides after oral administration was explored. The ultimate
goal of this work was to develop an oral dosage form to
deliver therapeutic peptides locally to the gastrointestinal
tract for the treatment of gastrointestinal inflammatory
disorders. In gastrointestinal inflammatory disorders, like
inflammatory bowel disease (IBD), there is a significant
unmet need to deliver immunomodulatory compounds di-
rectly to the intestinal mucosa to maximize local concen-
trations (thereby efficacy) and to minimize systemic toxicity.
A novel nuclear factor kappa-light-chain-enhancer of activat-
ed B cel ls (NF-κB) inhibitor pept ide, 8K-NBD
(KKKKKKKKGG-TALDWSWLQTE), has shown efficacies
in vitro and in vivo to inhibit activated NF-κB, a hallmark of
chronic inflammation, but not basal NF-κB activity, and
ameliorated intestinal inflammation in experimental IBD
models (17). The selective targeting of 8K-NBD to activated
NF-κB makes it an excellent therapeutic candidate and our
research interest. However, a significant challenge for oral
delivery of 8K-NBD is its chemical and biological degradation
in the gastrointestinal tract. To address this issue and deliver
8K-NBD or other water-soluble peptides locally to the
inflamed intestine, the peptide will be incorporated into w/o
microemulsions, which will be followed by incorporating the
optimal w/o microemulsion into enteric-coated hard gelatin
capsules to further enhance local peptide delivery in the GI
where needed. The current work is to test the first part of the
hypothesis that w/o microemulsions may provide protection
to the peptide incorporated when challenged in vitro and in
vivo, and serve as a viable oral delivery system to enhance
intestinal delivery of intact and biologically active water-
soluble peptides.
Based on some prior research results (10,11,13,14), w/o
microemulsions were developed using several commercially
available and pharmaceutically acceptable lipid-based exci-
pients. Miglyol 812 and Capmul MCM are medium-chain (C8/
C10) glycerides, generally recognized as safe, and meet the
requirements of the United States Pharmacopeia (USP) and
The National Formulary as medium-chain triglycerides and
mono- and di-glycerides (18,19), respectively. Tween 80 is
a nonionic surfactant included in the Food and Drug
Administration Inactive Ingredients Database for oral, IV, IM,
topical, andmany other preparations (20). Phase diagrams were
constructed and microemulsion windows were defined. Repre-
sentative microemulsions across the microemulsion window of
interest were characterized for formulation screening. To test
the protective effect of the w/o microemulsions, a fluorescent
labeled peptide, 5-(and-6)-carboxytetramethylrhodamine la-
beled HIV transactivator protein TAT (TAMRA-TAT), which
has similar cationic content and cell penetrating properties to
8K-NBD (21), was used as a model peptide. TAMRA-TATwas




Miglyol 812 (Caprylic/Capric triglycerides, neutral) was
provided by Sasol Germany GmbH (Eatontown, NJ, USA).
The fatty acid distribution of Miglyol 812 according to the
manufacturer is 57.7% caprylic acid (C8), 41.6% capric acid
(C10), 0.2% caproic acid (C6), and 0.3% lauric acid (C12).
Capmul MCM NF (C8/C10 mono- and di-glycerides) was
supplied by Abitec Corporation (Janesville, WI, USA).
Capmul MCM contains 53.6% of monoglycerides with 6.3%
free glycerol and its fatty acid distribution is 82.6% caprylic
acid and 17.4% capric acid. Tween 80 (polyoxyethylene
sorbitan monooleate, NF grade) was purchased from Spec-
trum Chemical MFG. Corporation (Gardena, CA, USA). 5-
(and-6)-Carboxytetramethylrhodamine-labeled TAT (47–57)
peptide (sequence: TAMRA-YGRKKRRQRRR) was pur-
chased from ANASPEC Inc. (Fremont, CA, USA). 4,4-
Difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-dodec-
anoic acid (BODIPY® FL C12) was purchased from Invi-
trogen (Eugene, OR, USA). Pancreatin from porcine
pancreas (8×USP specifications) was purchased from Sigma-
Aldrich Corporation (St. Louis, MO, USA). Tissue-Tek
Optimal Cutting Temperature (O.C.T.) Compound was
supplied by Sakura Finetek USA (Torrance, CA, USA).
Fluoro-Gel II, with 4′,6-diamidino-2-phenylindole (DAPI)
was purchased from Electron Microscopy Sciences (Hatfield,
PA, USA). Purified deionized water from a Milli-Q Advantage
System was used for all of the sample preparation. All other
chemicals were of analytical grade.
Microemulsion Preparation and Phase Diagrams
Three pseudoternary phase diagrams were constructed
to define the microemulsion windows using the following four
components: (a) Miglyol 812, a neutral oil of medium-chain
(C8/C10 triglyceride) fatty acid triglyceride, (b) Capmul
MCM, a low hydrophilic–lipophilic balance (HLB) surfactant
(HLB05.5–6.0), (c) Tween 80, a high HLB non-ionic
surfactant (HLB015.0), and (d) deionized water. Miglyol
812 and Capmul MCM were combined together at three
weight ratios (4:1, 65:22, and 2:1, w/w). The mixture of
Miglyol 812 and Capmul MCM at each weight ratio occupied
one apex of the ternary phase diagram, and Tween 80 and
water occupied the other two apices, respectively. Samples
were prepared by mixing appropriate amounts of Miglyol
812, Capmul MCM, Tween 80, and water in screw-capped
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scintillation vials at room temperature by shaking. Hundreds
of samples were prepared to define the phase boundaries in
each phase diagram. Each sample was further allowed to
equilibrate at room temperature for at least 24 h before
evaluation, and re-examined after 1 week. The existence of
the microemulsion window was identified as the region where
clear and transparent formulations were obtained upon visual
inspection. All samples were stored at room temperature and
the stability of each sample was assessed by visual inspection
in terms of clarity over time.
Microemulsion Characterization
Rheological Properties
The shear viscosity of the w/o microemulsions was
measured using a Brookfield LVDV-III + Cone and Plate
Rheometer (Brookfield Engineering Laboratories, Inc., Mid-
dleboro, MA, USA). The temperature was controlled by
coupling to a Brookfield TC-500 Refrigerated Bath. Instru-
ment calibration was performed using Brookfield silicone
viscosity standards. A CPE 40 spindle was utilized for sample
measurements. The shear stress, shear rate, and viscosity of a
series of representative microemulsion samples in the micro-
emulsion window of interest were measured. The relationship
of shear stress (dynes per square centimeter) versus shear
rate (per second) was utilized to assess the microemulsion
flow behavior.
Photon Correlation Spectroscopy
The droplet diameter of the microemulsion was measured
by photon correlation spectroscopy using a Zetasizer Nano ZS
(Malvern Instruments Inc., Worcestershire, UK) by backscat-
tering at a fixed angle of 173° at 25°C. All the samples were
measured in triplicates without any dilution.
Conductivity Measurements
The conductivity of the microemulsions was measured
using YSI 3200 conductivity meter (Yellow Spring Instru-
ments Co. Inc., Yellow Springs, OH, USA) coupled to YSI
3252 dip cell with a cell constant of 1.0 cm−1. The instrument
was calibrated using YSI conductivity calibrators. Samples
were measured at ambient temperature.
Freeze Fracture Transmission Electron Microscopy (FFTEM)
The morphology of the w/o microemulsion was charac-
terized by examination of freeze fracture replicas using
transmission electron microscopy (TEM). A tiny drop of
microemulsion was sandwiched between gold double-replica
mounts and frozen in liquid nitrogen-cooled Freon. Next, the
specimens were fractured in a Balzers BAF 400T freeze
fracture device at a stage temperature of −100°C under
vacuum. The fractured surfaces were shadowed unidirection-
ally with evaporated platinum and stabilized by carbon
evaporation. The resulting replicas and sample residues were
rinsed in distilled water, followed by washing in a solution of
5% sodium dichromate in 50% sulfuric acid. Replicas were
then transferred to distilled water, placed onto standard
copper microscopy grids, examined, and photographed with
a Zeiss EM 900 Transmission Electron Microscope at an
accelerating voltage of 60 kV (Carl Zeiss, Thornwood, NY,
USA).
Phase Inversion Behavior of W/O Microemulsions
To investigate the phase inversion behavior of w/o
microemulsions upon dilution, a lipophilic fluorescent marker
BODIPY FL C12 was incorporated into a selected w/o
microemulsion at the concentration of 0.1% by weight,
followed by dilutions of 2-, 5-, 10-, 50-, and 250-fold by
weight with water. The w/o microemulsion with BODIPY FL
C12 before and after dilution were examined under a Nikon
Eclipse TE 300 Fluorescence Microscope (Fryer Co. Inc.,
Huntley, IL, USA). The structure of the diluted sample was
further investigated by TEM. The w/o microemulsion after a
ten-fold dilution in water was negatively stained as follows: a
drop of diluted microemulsion in water was placed on a
copper grid, followed by removal of excess sample with filter
paper, and then a drop of 2% uranyl acetate was placed on
the copper grid for 2 min and subsequently examined by
TEM.
To elucidate the phase inversion behavior of samples
across the microemulsion window, microemulsions incorpo-
rating 5% water and with varying amounts of oil and
surfactants were diluted 100-fold in water by weight, and
the appearance and particle size of diluted samples were
assessed.
In Vitro Stability Studies in Modified Simulated
Intestinal Fluid
Modified simulated intestinal fluid (MSIF) was prepared
based on USP 34 (Solutions/Test Solutions). Briefly, 0.68 g of
monobasic potassium phosphate was dissolved in 75 mL of
water and mixed with 7.7 mL of 0.2 N sodium hydroxide.
Pancreatin (0.125 g) was added and mixed well. The pH was
adjusted to 6.8±0.1. Water was added to q.s. to 100 mL, and
then 1 mL was taken and diluted with 999 mL phosphate
buffer of pH 6.8 (10 mM) to a total of 1,000 mL.
TAMRA-TAT microemulsion was prepared by incorpo-
rating a defined amount of the TAMRA-TAT water solution
to the mixture of Miglyol 812, Capmul MCM, and Tween 80
to a final composition of Miglyol 812/Capmul MCM/Tween
80/TAMRA-TAT solution at the weight ratio of 62.8/21.2/7/9
with TAMRA-TAT at 60 μg/g of the microemulsion. In the in
vitro stability studies, 100 μL of MSIF was added to 50 mg of
TAMRA-TAT microemulsion or TAMRA-TAT solution
(60 μg/g) and incubated at 37°C. At specified time points,
the incubation was terminated by adding 300 μL of acetone
with 2% (v/v) of trifluoroacetic acid. The clear fraction
containing TAMRA-TAT was taken after centrifugation at
16,000×g for 10 min at 4°C, and then lyophilized and
reconstituted in acetonitrile/water with 0.1% trifluoroacetic
acid (19/81, v/v). TAMRA-TAT in the reconstituted sample
was determined by high-performance liquid chromatography
(HPLC) with fluorescence detection. Briefly, TAMRA-TAT
was detected using a reverse-phase column (Vydac 238MS
C18 5 μm, 4.6×250 mm, Grace Davison, Deerfield, IL, USA)
on a Thermo Finnigan Surveyor Plus HPLC system with a FL
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Plus detector using a binary gradient elution. Mobile phase A
consisted of 0.1% trifluoroacetic acid in acetonitrile and
phase B consisted of 0.1% trifluoroacetic acid in deionized
water. The initial eluent contained 19% phase A and 81%
phase B, and then phase Awas increased to 37% in 14.5 min.
The eluent composition was held at 37% phase A for 1 min
and then changed back to the initial composition and
equilibrated for 5 min before the next injection. The flow
rate was kept constant at 1 mL/min. The sample injection
volume was 10 μL and the excitation and emission wavelengths
were 545 and 579 nm, respectively.
In Vivo Studies for Intestinal Delivery
C57/BL6 female mice were obtained from the Charles
River Labs and maintained in specific pathogen-free con-
ditions. All experiments involving mice were carried out
according to the protocol approved by the UNC Institutional
Animal Care and Use Committee at the University of North
Carolina at Chapel Hill. Twelve-week-old C57/BL6 female
mice (18–20 g) were fed with standard chow without fasting
and grouped randomly and treated with TAMRA-TAT
microemulsion (2.5 mg/kg) or TAMRA-TAT solution
(2.5 mg/kg) or placebo microemulsion. TAMRA-TAT micro-
emulsion and TAMRA-TAT solution were prepared as
described above with TAMRA-TAT final concentration at
250 μg/g. Placebo microemulsion was prepared in the same
manner but using water as the aqueous phase instead of
TAMRA-TAT stock. All treatments were administered by
oral gavage with a single dose of 200 μL. Mice were sacrificed
4 h later and intestinal tissue was harvested. Intestinal
samples from duodenum, jejunum, ileum, and colon were
snap frozen in O.C.T. Compound and cut into 7-μm-thick
sections and placed onto microscope slides. Tissue on the
slides was counterstained with DAPI and examined using
fluorescence microscopy on an Olympus I×70 Fluorescence
Microscope (Olympus America). Fluorescence intensity (FI)
was quantified using ImageJ and expressed as integrated
density over the total field of each picture, the same region of
interest (ROI). The background was subtracted from each
picture by setting up a threshold value. Data are presented as
mean±SD. The statistical differences among the three treat-
ments (TAMRA-TAT microemulsion, TAMRA-TAT solu-
tion, and placebo microemulsion) and different intestinal
sections (duodenum, jejunum, ileum, and colon) were evalu-
ated by linear regression. The statistical significance between
the treatments for each intestinal section was assessed by one-
way ANOVA with Bonferroni post-tests. A value of p<0.05
was considered statistically significant.
RESULTS AND DISCUSSION
Phase Diagrams
The partial pseudoternary phase diagrams of Miglyol
812/Capmul MCM/Tween 80/water system were constructed
and are presented in Fig. 1. Miglyol 812 was the oil phase,
Tween 80 was the surfactant, Capmul MCM was the co-
surfactant, and water was the aqueous phase. Capmul MCM
has an HLB value of 5.5–6.0. It was utilized since it has the
same carbon chain length as Miglyol 812. Tween 80 is a water-
soluble surfactant with an HLB value of 15. The combination
of Capmul MCM and Tween 80 created a more flexible
water/oil interface, which in turn stabilized the w/o micro-
emulsions with an overall HLB value in the range from 7 to 9.
The weight ratio of Miglyol 812 to Capmul MCM was kept
constant at 4:1, 65:22, and 2:1 (w/w), respectively. The
advantage for keeping the weight ratio of Miglyol 812 to
Capmul MCM constant was that when the sample composi-
tion changed, the sample HLB value would change according
to the Tween 80 to Capmul MCM ratio in each phase
diagram. As described in the “Materials and Methods”
section, the microemulsion window was defined as the region
where formation of clear and transparent formulations upon
visual examination occurs. During the visual examination
process, the flow property of the samples was also considered
when the Tween 80 concentration was higher than 50% by
weight. Samples that were very viscous and unable to flow
when the vial was turned upside down were excluded from
the microemulsion window in this study. When comparing the
area obtained from these three phase diagrams, the apparent
microemulsion window was larger when the oil to co-
surfactant ratio was lower. However, during the formulation
screening process, a stable system with lower amount of
surfactants and similar water incorporation capacity was
preferred due to potential lower cytotoxicity (22). Meanwhile,
since a lower viscosity was also preferred and microemulsion
viscosity increases with the increase of Tween 80 concentra-
tion, the weight ratio of Miglyol 812/Capmul MCM at 65:22
(w/w) was selected in this study. With this ratio, micro-
emulsions with the Tween 80 concentration at 10% by weight
could incorporate up to around 9% water by weight. Clear
samples inside the microemulsion window were stored at
room temperature and monitored over time to assess whether
precipitation, phase separation, or any clarity change oc-
curred. All clear samples remained clear for at least 6 months
at room temperature, which clearly demonstrated the excel-
lent stability of the optimized systems.
A similar w/o microemulsion system has been reported
by Constantinides and colleagues (11,23,24) for systemic
peptide delivery. They reported greatly enhanced bioavail-
ability of Calcein and a water-soluble RGD peptide using the
system of Captex 355/Capmul MCM/Tween 80/Aqueous (65/
22/10/3, in percent w/w). In the current studies, Miglyol 812,
which has more defined fatty acid distribution and different
product specifications compared to Captex 355, served as the
oil phase and up to 9% water was incorporated in the w/o
microemulsions. The feasibility of these formulations for local
intestinal delivery of peptides via oral administration was
investigated both in vitro and in vivo.
Characterization of W/O Microemulsions
Rheological Properties and Conductivity
The rheological properties of microemulsion samples in
the microemulsion window were characterized by measuring
their shear stress versus shear rate. Several representative
samples across the microemulsion window incorporating 5%
water and varying amounts of Tween 80 (Fig. 2a) were
measured. As shown in Fig. 2b, all of the 11 microemulsion
samples showed apparent Newtonian fluid behavior wherein
291W/O Microemulsion for Peptide Intestinal Delivery
there was a linear relationship between shear stress and shear
rate. The viscosity of the 11 samples was obtained by linear
regression, and the slope of each regression line was the
apparent viscosity of each sample. As shown in Fig. 2c, the
viscosity of the microemulsion samples increased with an
increase in Tween 80 concentration. The viscosity data also
indicated the presence of a threshold (at the line around 42%
Tween 80). When the Tween 80 concentration was below this
threshold, the effect of Tween 80 on the microemulsion
viscosity was minor; however, when the Tween 80 concentra-
tion was above this threshold, the effect of Tween 80 on the
microemulsion viscosity was more pronounced. This phenom-
enon indicated that there might be a microemulsion structure
change when the Tween 80 concentration increased up to
around 42% by weight (Fig. 2c), which was consistent with
the results of the dilution studies discussed later. The detailed
microstructure is not yet understood. We hypothesize that
below this threshold, the w/o microemulsion droplets and
micelles coexisted, and the enhanced viscosity was due to the
increase of micelle number and size. Moreover, above this
threshold, there was the existence of a bicontinuous micro-
emulsion where Tween 80 and Miglyol 812 existed as two
continuous phases with Capmul MCM dispersed in the
interfacial layer and water dispersed in the continuous Tween
80 phase or associated with the polar head group of Tween 80
in the interfacial layer. Thus, the viscosity increase above this
threshold was attributed to the increase of bulk Tween 80.
To elucidate the sample properties inside the micro-
emulsion window, a series of microemulsion samples at
different ratio of Miglyol 812/Capmul MCM (65:22, w/w) to
Fig. 1. Partial pseudo-ternary phase diagrams of the system comprising Miglyol 812/Capmul MCM/
Tween 80/Water for the development of w/o microemulsions. The weight ratio of Miglyol 812/
Capmul MCM was kept constant at a 4:1, b 65:22, and c 2:1, respectively. The green dots represent
clear samples, the red dots represent turbid samples, and the shaded area is the microemulsion
window
Fig. 2. The mapping a, rheological property b, and viscosity c of 11 microemulsion samples containing 5% water inside the
microemulsion window for characterization. The sample numbers on the legend of b correspond to the samples shown in a
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Tween 80, such as 85:10, 70:25, 50:45, and 30:65, were
prepared and characterized. The viscosity of these micro-
emulsion samples is shown in Fig. 3a. At each fixed oil to
surfactant ratio, the viscosity increased slowly with increasing
water content. This increase was most likely due to the
increase in both droplets number and size which enhanced
the dispersed phase droplet interaction. In addition, consis-
tent with the results above, as the Tween 80 concentration
increased, the viscosity increased accordingly.
Conductivity is an important parameter which might
reflect the microstructure of the microemulsions (25). The
conductivity of series of microemulsion samples with different
oil to surfactant ratios is shown in Fig. 3b. With increasing
water concentration at each fixed oil to surfactant ratio, the
conductivity increased accordingly, most likely due to the
increase in both droplets number and size (26). Related, with
increasing Tween 80 concentration, the conductivity also
gradually increased, which was probably due to the increased
interaction between droplets which facilitated the ion ex-
change between droplets (26). Overall, the low conductivity
of these microemulsions was an indication of the formation of
w/o microemulsions (27).
Photon Correlation Spectroscopy and FFTEM
Photon correlation spectroscopy was employed for
microemulsion droplet size analysis. As shown in Fig. 3c,
samples in the microemulsion window with water concentra-
tion higher than 3% and Tween 80 concentration lower than
20% showed smaller polydispersity index (PI) with more
uniform droplet diameter in the range of 10–40 nm (data not
shown). While samples in the microemulsion window with
Tween 80 concentration at 20% (w/w) or higher, or with
water concentration lower than 3% (w/w) were polydisperse
with a greater PI. The size analysis reports indicated that
those samples with a larger PI (e.g., PI>0.3) were too
polydisperse for data analysis. The high PI values of the
microemulsion samples were likely an indication of the
presence of an excess amount of Tween 80 surfactant. Since
samples with uniform size distribution were preferred, micro-
emulsion samples with smaller PI (PI<0.1) were identified for
further evaluation.
To investigate the morphology and confirm the droplet
size of the w/o microemulsions, FFTEM was utilized. Figure 4
shows the FFTEM results of one of the placebo micro-
emulsion formulations of interest (Table I), which was plotted
and highlighted by a red circle and a red arrow in Fig. 3c. The
droplets were spherical with an average diameter around
20 nm, which was consistent with the results obtained by
photon correlation spectroscopy.
Phase Inversion Behavior of W/O Microemulsions
The w/o microemulsions developed in this work were
primarily designed for oral delivery route. After oral admin-
istration, the w/o microemulsions will likely be phase-inverted
into o/w emulsions and/or water-in-oil-in-water (w/o/w)
double emulsions. Since the phase inversion behavior might
affect the in vivo fate of the drug incorporated (28), it is
important to investigate this behavior. The first experiment
performed was a dilution study using fluorescence microsco-
py. A fluorescent fatty acid, BODIPY FL C12, was dissolved
in a w/o microemulsion formulation (84% mixture of Miglyol
812/Capmul MCM (65:22, w/w), 10% Tween 80, and 6%
water), and then diluted in water by different dilution factors.
The purpose of this dilution study was, (1) to confirm the
phase inversion behavior and (2) to find out the minimal
dilution factor required for the phase inversion to occur. As
expected, before dilution, the microemulsion with BODIPY
FL C12 appeared clear with strong green fluorescence
Fig. 3. The viscosity a, conductivity b, and polydispersity index c of microemulsion samples across
the microemulsion window with the weight ratio of Miglyol 812/Capmul MCM at 65:22
(w/w). Each data point is color coded and the height of each bar also indicates the relative value
of each data. The circled data point with a red arrow corresponds to the placebo microemulsion
shown in Table I
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(Fig. 5a). However, upon a five-fold or more dilution, the w/o
microemulsion was readily inverted into coarse o/w-type
emulsions with large and polydisperse green fluorescent
droplets (Fig. 5c–f), while with a two-fold dilution, the w/o
microemulsion was probably partially phase-inverted as a
large continuous green fluorescent area occupied close to half
of the examined field (Fig. 5b). This study visually demon-
strated the occurrence of phase-inversion behavior of w/o
microemulsions upon dilution.
To further examine the detailed structure of the resulting
emulsion from dilution, a w/o microemulsion formulation
(84% mixture of Miglyol 812/Capmul MCM (65:22, w/w),
10% Tween 80, and 6% water) diluted ten-fold by weight in
water was negatively stained using 2% uranyl acetate, and
subsequently examined using TEM. The results showed that
the large droplets seen under a fluorescence microscope
contained numerous smaller droplets associated together
(Fig. 6), and there was no clear indication of the formation
of double or multiple emulsions. The dark area between
those smaller droplets might be an indication of the presence
of aqueous phase, which may be able to host water-soluble
drug molecules and protect the drug molecules from acidic
and enzymatic degradation. The oil phase might also be able
to bring the peptide to the proximity of mucosa surface
quicker so that the peptide has a greater chance to be
internalized before degradation occurs in the lumen. The
phase inversion studies using fluorescence microscopy togeth-
er with TEM provide a high resolution perspective of phase
inversion from w/o microemulsions to coarse o/w emulsions
upon dilution using aqueous phase.
To provide an overview of the phase inversion behavior
of samples across the microemulsion window, samples with
5% water and different oil to surfactant ratios were diluted
100-fold in water by weight. The results showed that as the
weight ratio of Miglyol 812/Capmul MCM (65:22, w/w) to
Tween 80 was 40:55 (#7 in Fig. 7a) or less, such as 40:60,
30:65, 20:75, 10:90 (corresponding to #8, 9, 10, and 11 in
Fig. 7a), the microemulsion was inverted to stable clear or
translucent microemulsion (Fig. 7a) with uniform size distri-
bution (Fig. 7b). However, when the weight ratio of Miglyol
812/Capmul MCM (65:22, w/w) to Tween 80 was 45:50 (#6 in
Fig. 7a) or higher, the microemulsion was inverted to turbid
emulsions. These results were consistent with the viscosity
data which showed the existence of a threshold around the
line of 42% Tween 80 by weight. Together, the viscosity data
and dilution data indicated there might be a microstructure
change of microemulsions with Tween 80 concentration close
to 42–50% by weight in the microemulsion window of the
selected phase diagram. In addition, since the microemulsion
with the weight ratio of Miglyol 812/Capmul MCM (65:22,
w/w) to Tween 80 at 40:55 (#7 in Fig. 7a) or lower exhibited
similar dilution properties of self-microemulsifying drug
delivery systems (29,30), these microemulsions might find
applications to enhance oral absorption of poorly water-
soluble and/or poorly permeable drugs, which is beyond the
scope of the current study.
In Vitro Stability Studies in MSIF
MSIF was prepared using pancreatin from porcine
pancreas, which contains a broad spectrum of digestive
enzymes, including amylase, trypsin, lipase, ribonuclease,
and protease. The pancreatin from porcine pancreas contains
similar enzymes as the pancreatic fluid which a drug might
encounter when it enters the intestines following oral
administration. To test the hypothesis that w/o microemulsion
can provide protection to the water-soluble peptide incorpo-
rated from enzymatic degradation, the stability of TAMRA-
TAT in microemulsion and TAMRA-TAT in solution in MSIF
at 37°C was determined by HPLC with fluorescence detec-
tion. The TAMRA-TAT peak in HPLC chromatogram was
well separated from its degradation products. Spike-recovery
studies of TAMRA-TAT in the presence of placebo micro-
emulsion using the sample processing method described
under “Materials and Methods” section was 100.11±6.24%
(n03). The kinetics of TAMRA-TAT degradation was
determined by following the loss of TAMRA-TAT as a
function of time (31). As shown in Fig. 8, the kinetics of
TAMRA-TAT microemulsion and solution in MSIF followed
pseudo-first-order rates, which were described by the equa-
tion y0b×e−kt. In this equation, y represents the percentage
(normalized concentration) of TAMRA-TAT at time t, b is
the initial TAMRA-TAT concentration (percentage), t is the
reaction time in minutes, and k is the pseudo-first-order rate
constant (31). For TAMRA-TAT solution, the TAMRA-TAT
degradation kinetics fit the equation y096.78 e−0.1034 t (R20
0.9977), and the half-life (t1/2) calculated from the resulting
Fig. 4. The FFTEM of a selected placebo water-in-oil (w/o)
microemulsion
Table I. Characterization of Placebo and TAMRA-TAT W/O Microemulsions (n03)
w/o Microemulsions Viscosity(cP) Mean droplet diameter (nm) Polydispersity index Conductivity (μS/cm)
Placebo ME 43.7±1.2 20.6±2.3 0.023±0.030 0.690±0.013
TAMRA-TAT ME 43.2±0.6 21.4±3.3 0.059±0.036 0.681±0.017
This w/o microemulsion composition was Miglyol 812/Capmul MCM/Tween 80/Aqueous at the weight ratio of 62.8/21.2/7/9. The aqueous for
placebo microemulsion (ME) is water and for TAMRA-TAT microemulsion is TAMRA-TAT stock
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rate constant was 6.7 min. For TAMRA-TAT microemulsion,
the TAMRA-TAT kinetics followed y091.56 e−0.0357 t (R20
0.991) with a calculated t1/2 of 19.4 min, which was nearly
three-fold greater than that of TAMRA-TAT in solution.
The HIV TAT (47–57) moiety in TAMRA-TAT contains
positively-charged amino acids arginine and lysine, which
makes it highly susceptible to proteolysis by tryptic enzymes
(31). A review article (32) pointed out seven potential trypsin
cleavage sites (48, 49, 50, 51, 52, 54, and 56), and Grunwald et
al. (31) also identified a few fragments by MS in in vitro TAT
(47–57) proteolysis studies, which include GRKKRRQRRR,
GRKKRRQRR, GRKKRRQR, YGRKKRRQR, and
YGRKKRRQRR. In our study, the kinetics of TAMRA-
TAT degradation was followed by the detection of the loss of
parent TAMRA-TAT. The stability of the TAMRA-TAT was
significantly enhanced by the w/o microemulsion when
challenged by MSIF. A similar protective effect from a
different w/o microemulsion system to a rhPTH1-34 peptide
in the presence of pepsin and trypsin was reported by Guo et
al. (33) in an in vitro enzymatic stability study. Another study
by Cheng et al. (10) stated that after their w/o microemulsion
system was phase inverted following a 800-fold dilution, only
7% loaded peptide was detected in the aqueous phase and
the rest of the peptide was still detected in the upper coarse
emulsion after separation by centrifugation. Although, there
was no direct evidence, it is possible that even after dilution,
Fig. 5. Fluorescence microscopy of water-in-oil (w/o) microemulsion upon dilution in DI water. a W/O microemulsion with
BODIPY FL C12, b w/o microemulsion with BODIPY FL C12 by a two-fold dilution, c five-fold dilution, d ten-fold dilution,
e 50-fold dilution, and f 250-fold dilution, respectively. The composition of the w/o microemulsion was Miglyol 812/Capmul
MCM/Tween 80/water at the weight ratio of 62.8/21.2/10/6. All the images shown were taken with ×10 objective lens (with a
total of ×100 magnification)
Fig. 6. TEM of a w/o microemulsion sample after a ten-fold dilution.
The w/o microemulsion composition was the same as stated under
Fig. 5.
Fig. 7. The phase inversion behavior of w/o microemulsions. a The
picture shows the phase inversion behavior of samples across the
microemulsion window. Eleven microemulsion samples with the
weight ratio of Miglyol 812/Capmul MCM (65:22, w/w) to Tween 80
at 85:10, 80:15, 70:25, 60:35, 50:45, 45:50, 40;55, 40:60, 30:65, 20:75,
and 10:90 were diluted 100-fold by weight with water, respectively. b
The droplet size analysis of diluted samples corresponds to samples
labeled in a
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the peptide loaded to the microemulsion might still be
associated with the coarse emulsion when phase inversion
happens, which renders protection to the loaded peptide from
enzymatic degradation. These peptide stability data further
supported the results from the following in vivo mouse
studies and the hypothesis that w/o microemulsion may
provide protection to the peptide incorporated in the
enzymatic environment compared to peptide in water solution.
In Vivo Studies for Intestinal Delivery
The initial aim of this work was to develop and optimize
a w/o microemulsion that has the potential to increase the
delivery of a potent peptide to inflamed intestinal tissue. If
successful, the w/o microemulsion could then be incorporated
into enteric-coated hard gelatin capsules to further enhance
the delivery where and when needed. Therefore, it was not
the intention to develop a w/o microemulsion that would be
given orally as an oral microemulsion drink. To facilitate the
initial aim, a commercially available fluorescent TAMRA-
TAT peptide was used as a model therapeutic peptide,
considering it has similar cationic content and cell-penetrating
properties to 8K-NBD, a potent NF-κB inhibitor. TAMRA-
TAT was loaded to one of the w/o microemulsion templates
(Table I) and orally gavaged to mice. TAMRA-TAT solution
and placebo microemulsion were administered in parallel as
controls. The physical properties of the w/o microemulsion
with and without TAMRA-TAT are shown in Table I. The
actual TAMRA-TAT loading was 96.6±1.69% (n05) com-
pared to the theoretical loading as measured by HPLC.
The intestinal distribution of TAMRA-TAT was evaluat-
ed using a semi-quantitative method, fluorescence microsco-
py. The FI was quantified using ImageJ and represented as
integrated density over the same ROI. As shown in Fig. 9, the
FI from the treatment of TAMRA-TAT microemulsion in all
the intestinal sections are significantly greater than that from
the treatment of TAMRA-TAT solution or placebo micro-
emulsion. Linear regression of FI versus treatments
(TAMRA-TAT microemulsion, TAMRA-TAT solution, and
placebo microemulsion) and FI versus intestinal sections
(duodenum, jejunum, ileum, and colon) showed p values of
1.51×10−26 and 3.52×10−6, respectively, which indicated FI
was strongly correlated with the treatments, meanwhile, FI
was associated with intestinal sections, but to a lesser extent.
To compare the overall FI in the small intestines to that in the
large intestine, the linear regression coefficients of FI versus
treatments in each intestinal section were calculated. The
average linear regression coefficient from the duodenum,
jejunum, and ileum was 5.9-fold greater than that from the
colon, which suggested that overall, the FI difference among
three treatments in the small intestine was greater than that in
the large intestine. Representative images from each
intestinal section are shown in Fig. 10.
In summary, the in vivo mouse experiment showed that FI
resulting from the TAMRA-TAT microemulsion treatment was
significantly greater than that from the TAMRA-TAT solution
or placebo microemulsion treatment in all intestinal sections.
Although a semi-quantitative method was employed in these in
vivo studies, it was likely that the fluorescence observed was
mostly due to intracellular fluorescence since the intestine tissue
was washed before fluorescence imaging. Moreover, only intact
TAMRA-TAT should be taken up intracellularly, so the
presence of more fluorescence in the tissue was an indication
of the presence of more intracellular TAMRA-TAT. Therefore,
results from the in vivo studies showed that the TAMRA-TAT
w/o microemulsion enhanced the intestinal delivery of
TAMRA-TAT compared to the TAMRA-TAT solution and
placebo microemulsion. However, the overall FI in the small
intestine was still greater than that in the large intestine after
oral administration, which will be addressed by encapsulation of
the w/o microemulsion into enteric-coated capsules to facilitate
the local delivery to the target region of the intestinal tract, such
as the colon. Some preliminary experiments on the compatibility
of the w/omicroemulsion and hard gelatin capsules were carried
out. The results showed that hard gelatin capsules containing
Miglyol 812, Capmul MCM, Tween 80, and the w/o micro-
emulsion, respectively, remained stable at room temperature for
at least 1 year. There were no obvious changes to capsule
stiffness or shape. Thew/omicroemulsion inside the hard gelatin
capsules stayed clear with the same particle size after 1 year at
room temperature. The compatibility of the excipients in w/o
microemulsions contained in hard gelatin capsules was also
Fig. 8. The stability of TAMRA-TAT microemulsion versus
TAMRA-TAT solution (Soln.) in MSIF at 37°C. The remaining
TAMRA-TAT was normalized with respect to the initial concentra-
tion. Three samples were prepared for each time points for both
TAMRA-TAT microemulsion and TAMRA-TAT solution. Data are
presented as mean±SD (n03) on a logarithmic scale. The degrada-
tion profiles of TAMRA-TAT in microemulsion and solution in MSIF
at 37°C were described by pseudo-first-order kinetics
Fig. 9. The fluorescence intensity in different mouse intestinal
sections after oral administration of TAMRA-TAT microemulsion
(n04 mice), TAMRA-TAT solution (Soln.; n04 mice), and placebo
microemulsion (n03 mice). The data are presented as mean±SD.
***p<0.001
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supported by a review (34). After capsules containing w/o
microemulsion were enteric coated, the microemulsion stayed
clear and stable in enteric-coated capsules at room temperature
or at 4°C in a refrigerator for at least 1 week before being used
for experiments. Results from the mouse experiments were also
supported by the data from the TAMRA-TAT in vitro stability
studies, which provided direct evidence on the protective effect
of w/o microemulsion to the peptide incorporated when
challenged by the enzyme-containing environment. Together,
the in vitro and in vivo studies indicated that the w/o micro-
emulsion system may serve as a viable oral delivery vehicle to
enhance the intestinal delivery of water-soluble peptides.
Intestinal delivery of peptides and proteins has been
reported (35), but most of the reports have focused on the
improvement of systemic absorption. There are quite limited
reports on the local intestinal delivery of peptides or proteins
for the treatment of local pathologies, like IBDs. Coco et al.
(36) investigated the potential of three polymeric nano-
particles for colon-specific protein delivery via in vitro and
ex vivo approaches. Hong et al. (37) reported promising
peptide local intestinal delivery using colon-targeted enteric-
coated capsules. In our study, w/o microemulsions as a
potential oral delivery vehicle for local intestinal delivery of
a cell-permeable peptide was investigated. The hydrophobic
oil phase, Miglyol 812, together with Capmul MCM served as
a protective vehicle to shield the peptide from acidic and
enzymatic attack and protect the peptide incorporated during
transition. In addition, Miglyol 812 as medium-chain trigly-
cerides might also be converted to monoglycerides in the
presence of lipase and enhance intracellular delivery (38). In
our study, the protective effect of the w/o microemulsion to
the peptide incorporated was clearly presented. Incorporation
of therapeutic peptides into the w/o microemulsion developed
in the current study followed by encapsulation into enteric-
coated capsules will be evaluated in larger animal models,
like pig colitis models and will be the focus of our future
studies.
CONCLUSIONS
This work demonstrates the potential of using w/o
microemulsions as an oral delivery vehicle to deliver a cell-
permeable peptide to the local murine intestines. Water-in-oil
microemulsions were developed, characterized, and evaluat-
ed. The in vitro peptide stability studies provided direct
evidence of the protective effect of the w/o microemulsion to
the peptide incorporated against enzymatic degradation. The
in vivo mouse studies exhibited enhanced intestinal delivery
of the model peptide TAMRA-TAT to the mouse small and
large intestines using the w/o microemulsion system. Since the
w/o microemulsions developed in this work might exhibit dual
mechanisms by providing both enhanced protection and
intracellular delivery, their applications are not limited to
cell-penetrating peptides. Meanwhile, the w/o microemulsions
developed in this work were thermodynamically stable, and
formed spontaneously at room temperature without the
application of heating or high shear stress. These micro-
emulsion systems may serve as a platform for oral intestinal
delivery of water-soluble and heat-labile peptides or proteins
by their incorporation into enteric-coated capsules.
Fig. 10. Representative fluorescence microscopic images from intestines of C57/BL6 mice treated
with TAMRA-TAT microemulsion, TAMRA-TAT solution (Soln.) and placebo microemulsion
(ME) 4 h after oral gavage. Scale bar represents 50 μm
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